Clear All
11120 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
50881-0027-01 50881-0027 Pemigatinib PEMAZYRE 9.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3 Oral Apr 17, 2020 In Use
50881-0026-01 50881-0026 Pemigatinib PEMAZYRE 4.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3 Oral Apr 17, 2020 In Use
50881-0015-60 50881-0015 Ruxolitinib Jakafi 15.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral Nov 16, 2011 In Use
00781-3258-70 00781-3258 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous May 31, 2022 In Use
00069-0251-60 00069-0251 CRIZOTINIB Xalkori 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK, HGFR, ROS1, RON Oral Nov 20, 2023 In Use
00378-9045-05 00378-9045 Cysteamine bitartrate Cystagon 150.0 mg/1 Chemotherapy Cystine-Depleting Agent Oral Apr 11, 2005 In Use
63323-0123-10 63323-0123 Methotrexate Sodium Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intravenous Sep 10, 2001 In Use
63323-0883-05 63323-0883 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Apr 14, 2000 In Use
50881-0010-60 50881-0010 Ruxolitinib Jakafi 10.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1 and JAK 2 (Janus Kinase Inhibitor) Oral Nov 16, 2011 In Use
50881-0010-01 50881-0010 Ruxolitinib Jakafi 10.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1 and JAK 2 (Janus Kinase Inhibitor) Oral Nov 16, 2011 In Use
70771-1521-03 70771-1521 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Apr 30, 2020 In Use
59676-0966-02 59676-0966 doxorubicin hydrochloride Doxorubicin Hydrochloride liposome 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Jun 26, 2017 Oct 31, 2020 No Longer Used
54879-0021-01 54879-0021 CYCLOPHOSPHAMIDE CYCLOPHOSPHAMIDE 25.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral May 8, 2018 In Use
60505-3817-03 60505-3817 Dasatinib Dasatinib 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 3, 2024 In Use
75834-0144-05 75834-0144 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec 7, 2021 In Use
55390-0304-05 55390-0304 Paclitaxel Paclitaxel Chemotherapy Antimitotic Agent Taxane Intravenous Dec 1, 2006 Apr 30, 2013 No Longer Used
66336-0338-30 66336-0338 METHOTREXATE Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Dec 7, 1953 In Use
25021-0202-05 25021-0202 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Oct 31, 2013 Nov 30, 2016 No Longer Used
63323-0126-00 63323-0126 GEMCITABINE GEMCITABINE 2.0 g/50mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous May 17, 2011 In Use
55390-0293-01 55390-0293 Etoposide Etoposide Chemotherapy Plant Alkaloid Epipodophyllotoxins Intravenous Feb 1, 1997 Jun 30, 2013 No Longer Used
66758-0950-02 66758-0950 Docetaxel Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Jul 22, 2015 In Use
00078-0682-66 00078-0682 Dabrafenib Tafinlar 50.0 mg/1 Chemotherapy Enzyme Inhibitor BRAF Oral Apr 12, 2016 In Use
70121-2461-01 70121-2461 Pemetrexed disodium PEMRYDI RTU 500.0 mg/50mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jun 6, 2023 In Use
51991-0376-90 51991-0376 IMATINIB MESYLATE IMATINIB MESYLATE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb 8, 2019 Mar 31, 2023 No Longer Used
54288-0106-03 54288-0106 Melphalan Hydrochloride Melphalan Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Sep 30, 2020 In Use

Found 11120 results — Export these results